Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors

Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas

(2012) Alcides Chaux et al.   HUMAN PATHOLOGY

Targeting mTOR in renal cell carcinoma

(2010) Gary R. Hudes   CANCER

Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001

(2010) Steffen Wedel et al.   LIFE SCIENCES

Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2

(2009) M. Gupta et al.   BLOOD

Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies

(2009) Janice P. Dutcher et al.   MEDICAL ONCOLOGY

Combination Strategy Targeting the Hypoxia Inducible Factor-1  with Mammalian Target of Rapamycin and Histone Deacetylase Inhibitors

(2008) H. M.W. Verheul et al.   CLINICAL CANCER RESEARCH

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

(2008) Monica M. Mita et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET